Pfizer Inc said it expects to file anew drug application in the U.S. and in other markets this yearfor sertraline, a treatment for depression.    In its annual report, Pfizer said that in addition to thedrug's anti-depressant action, sertraline is currentlyundergoing studies to explore its ability to promote weightloss. Company officials were not immediately available tocomment further.    Eli Lilly and Co's &lt;LLY> Prozac, an antidepressant awaitingmarketing approval, has shown promise in promoting weight loss.    Pfizer also said it plans to file for U.S. marketingapproval for certrizine, a "novel" antihistamine for hay fever,and other allergic reactions.    In 1986, Pfizer earned 660 mln dlrs or 3.90 dlrs per shareon revenues of 4.5 billion dlrs. Reuter&#3;